News Archive
Cantargia shows in-vivo proof of concept in malignant melanoma »
12-02-09
More attention on Cantargia in the internationally recognized magazine "BioCentury" »
12-01-31
ProNoxis has secured SEK 4.0 million in a new round of financing »
12-01-25
New rights issue in LU Bio February 2012 »
12-01-18
LUIS - LU Bio collaboration generates two new companies »
11-08-30
New investment in ProNoxis »
11-06-17
Attention on XImmune in BioCentury »
11-04-13
Cantargia builds power »
11-02-21
Continued progress in XImmune »
11-02-07
LU Bio acknowledged in high profile publication SciBX »
11-01-22
LU Bio sales of holdings »
10-12-08
Report on LU Bio portfolio company ProNoxis published in BioCentury »
10-10-07
LU Bio has decided to close the portfolio company Auril »
10-09-30
Article on Cantargia published in SciBX regarding “Homing in on CML stem cells“ »
10-09-17
LU Bio and Bio-Medisinsk Innovasjon AS in Oslo starts new co-operation »
10-09-13
LU Bio portfolio company Cantargia in the newsroom »
10-08-31
LU Bio dispose Oncorel holdings »
10-04-14
LU Bio portfolio company XImmune in the newsroom »
10-03-25
Dermagen reports successful phase I/IIa clinical trial »
09-12-02
LU Bioscience increases position in ProNoxis »
09-11-12
Successful findings from our portfolio company Auril noticed »
09-09-07
New investment dealing with temperature reduction in patients »
09-06-23
LU Bio announces a continued investment in Cytoguide ApS »
09-06-02
New portfolio company ProNoxis established »
09-06-01
Open seminar at Biomedical Center, Lund University, on March 25 »
09-03-15

ProNoxis has secured SEK 4.0 million in a new round of financing

Share
| Print |
Tell a colleague

Tell a colleague about this

Your name
Recipient E-mail

Share this page

LinkedIn
Windows Live
Facebook
Google Bookmarks
del.icio.us
digg
FriendFeed
MySpace
With operations proceeding as planned, ProNoxis has secured SEK 4.0 million in a new round of financing. Signaling confidence in ProNoxis development to date, lead investor LU Bioscience has invested SEK 2.0 million and Karolinska Development SEK 2.0 million. The investment will give proof of principal in an arthritis model from lead candidates and continued lead development. LU Bio and Karolinska Development now hold 32 % and 22 % of ProNoxis, respectively. Redoxis AB holds the remaining 46 %.






 

+46 (0)46 286 48 20
info@lubio.se
Ideon, Alfa 5
SE 223 70 Lund, Sweden
Lund University Bioscience AB
Contact us